Depression, stress could moderate viability of COVID-19 antibodies: Study ANI | Updated: Jan 17, 2021 22:12 IST
Washington [US], January 17 (ANI): A study published in Perspectives on Psychological Science shows that downturn, stress, loneliness, and chronic weakness practices can debilitate the body s immune system and lower the adequacy of specific antibodies.
The report proposes that the equivalent might be valid for the new COVID-19 immunizations that are being developed and the beginning phases of worldwide distribution.
Fortunately, it may be possible to reduce these negative effects with simple steps like exercise and sleep.
Vaccines are among the safest and most effective advances in medical history, protecting society from a wide range of otherwise devastating diseases, including smallpox and polio. The key to their success, however, is ensuring that a critical percentage of the population is effectively vaccinated to achieve so-ca
Beware! Depression, stress may reduce efficacy of COVID-19 vaccines; read details
orissapost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from orissapost.com Daily Mail and Mail on Sunday newspapers.
Estrés y depresión pueden reducir la efectividad de vacunas
ejecentral.com.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ejecentral.com.mx Daily Mail and Mail on Sunday newspapers.
NEW DELHI: Depression, stress and loneliness can weaken the body s immune system, and lower the effectiveness of certain vaccines, including the new COVID-19 preventives that are in development and the early stages of global distribution, scientists say. According to a report accepted for publication in the journal Perspectives on Psychological Science, simple interventions, including exercise and getting a good night s sleep in the 24 hours before vaccination, may maximise the vaccine s initial effectiveness. The researchers noted that even though rigorous testing has shown that the COVID-19 vaccines approved for distribution in the US are highly effective at producing a robust immune response, not everyone will immediately gain their full benefit.